Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

NCT03263559 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

PROCEDURE: Haploidentical Bone Marrow Transplantation
DRUG: Hydroxyurea
DRUG: Rabbit-ATG
DRUG: Thiotepa
DRUG: Fludarabine
DRUG: Cyclophosphamide
RADIATION: Total Body Irradiation
DRUG: Mesna

Sponsor

Medical College of Wisconsin

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]